Bortezomib for severe autoimmune encephalitis after rituximab
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can give informed consent
- Your diagnosis is severe autoimmune encephalitis (you’re able to do basic self-care with help; mRS 3 or higher)
- Your blood or spinal fluid test shows autoantibodies against neuronal (nerve cell) surface proteins
- You have already been treated with rituximab before starting this study
- If you can become pregnant: your pregnancy test is negative, and you avoid pregnancy during the study
- You must not be on ongoing glucocorticoid or rituximab treatment during the study (the last dose must be before bortezomib starts)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
This study tests whether a nasal spray containing stem cell products can help people recover from autoimmune encephalitis, a condition where the body's immune system attacks the brain. It may reduce symptoms like confusion, memory problems, or seizures.
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
This trial tests a chemotherapy combination that includes bortezomib for people whose acute lymphoblastic leukemia (ALL) has come back or not responded to previous treatments. It aims to offer a new option for those who haven't tried bortezomib before.
This trial tests whether rituximab, a medication that calms the immune system, can help people with certain nerve or brain conditions linked to a specific antibody. It aims to reduce symptoms or prevent the disease from getting worse.
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.